Document 0458
 DOCN  M9460458
 TI    Utility of quantitative enzyme immunoassay reactivity for predicting
       human immunodeficiency virus seropositivity in low- and high-prevalence
       populations.
 DT    9404
 AU    Hou X; Breese PL; Douglas JM Jr; Denver Disease Control Services,
       University of Colorado Health; Sciences Center, Colorado 80204.
 SO    J Clin Microbiol. 1994 Jan;32(1):220-3. Unique Identifier : AIDSLINE
       MED/94172028
 AB    To assess the utility of quantitative enzyme immunoassay (EIA)
       reactivity for predicting human immunodeficiency virus seropositivity,
       we evaluated 22,823 serum samples from homo- and bisexual men,
       heterosexual intravenous drug users, and other heterosexuals with
       initial screening by EIA, retesting of reactive samples in duplicate,
       and confirmatory Western blot (immunoblot) testing. Quantitative EIA
       reactivity was determined by a mean of the optical density ratio of the
       three assays performed for each reactive specimen. A total of 1,773
       samples (7.8%) were repeatedly reactive, and 1,747 (7.7%) were confirmed
       Western blot positive. All 26 EIA-reactive-Western blot-negative samples
       had low-level EIA reactivity (ratio < 2.2), while most (86%) of the
       Western blot-positive samples had high-level reactivity (ratio, > 3.0).
       The positive predictive value for samples with moderate-to-high-level
       EIA reactivity (ratio, > 2.2) was 100% for all risk groups. These
       results support the value of quantitative EIA reactivity in predicting
       human immunodeficiency virus seropositivity and suggest that
       confirmatory testing of specimens with high-level reactivity is not
       necessary in all situations.
 DE    Algorithms  Blotting, Western  Colorado/EPIDEMIOLOGY  Comparative Study
       Evaluation Studies  Forecasting  Human  HIV
       Seropositivity/*BLOOD/DIAGNOSIS/EPIDEMIOLOGY  HIV Seroprevalence
       *Immunoenzyme Techniques  Male  Population Surveillance  Prevalence  Sex
       Behavior  Substance Abuse, Intravenous  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).